Compare Crispr Therapeutics AG (CRSP) vs Icl Group Ltd (ICL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Icl Group Ltd — how do they compare? Crispr Therapeutics AG trades at $53.98 (market cap $5.23B), while Icl Group Ltd trades at $5.3 (market cap $6.94B). The key difference: Icl Group Ltd is the larger of the two by market cap, and Icl Group Ltd pays a 3.86% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | ICL | |
|---|---|---|
Market Cap | $5.23B | $6.94B |
Sector | Health | Basic Materials |
52-Week High | $76.78 | $6.84 |
52-Week Low | $44.34 | $4.80 |
Enterprise Value | $3.65B | $9.58B |
Dividend Yield | — | 3.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $54.02, up 0.95% on the day, with strong technical momentum and bullish moving average signals. The company reported a Q2 2026 loss of $0.94 per share, beating estimates, while revenue growth is driven by CASGEVY sales expansion. Analyst sentiment remains positive with a $82.67 consensus price target representing 53% upside potential.
Despite promising pipeline developments and strong analyst support, CRSP faces significant fundamental challenges including negative profit margins, substantial cash burn, and high valuation multiples. The stock's near-term performance will depend on successful clinical trial outcomes and commercial execution of its gene-editing therapies.
ICL trades at $5.465, up 2.34% today, with a bullish technical signal from moving averages. The company reported Q2 2026 EPS of $0.12, beating estimates, and revenue is projected to grow to $7.7B in 2026. Recent news highlights strong quarterly results and a senior notes offering. The stock shows a neutral sentiment from oscillators, while analyst consensus is entirely Hold.
The outlook is mixed; earnings beats and operational improvements support upside, but declining net margins and a unanimous Hold rating from analysts suggest limited near-term catalysts. Key risks include raw material cost pressures and foreign exchange volatility, which could impact profitability despite positive cash flow trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →
